Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries
Sabine Vogler*, 1, Nina Zimmermann1, Christine Leopold1, Claudia Habl1, Jan Mazag2
Identifiers and Pagination:Year: 2013
First Page: 1
Last Page: 10
Publisher Id: TOPHARMEJ-5-1
Article History:Received Date: 6/2/2013
Revision Received Date: 14/4/2013
Acceptance Date: 20/04/2013
Electronic publication date: 17/5/2013
Collection year: 2013
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The study aimed to survey price reductions such as discounts and rebates granted for medicines used in hospitals.
We collected official list prices and actual hospital prices of 12 medicines in 25 hospitals in European countries (Austria, the Netherlands, Norway, Portugal and Slovakia).
In all five countries price reductions were granted for some of the medicines surveyed. They usually had the form of discounts; additionally, ex-post rebates were reported from Austria and Portugal. For oncology, anti-inflammatory diseases, neurology-multiple sclerosis and blood no price reductions or only minor discounts/rebates on medicines prices were surveyed, whereas discounts/rebates were routinely granted for cardiovascular medicines and medicines for immunomodulation. Price reductions of 100 percent were found in Austria, Portugal and Slovakia. With the exception of Slovakia, the extent of the discounts/rebates did not differ substantially among the hospitals of a country. The highest median price reductions were identified in Norway, followed by the Netherlands. Price reductions for medicines procured by central tendering tended to be higher than those obtained in decentralized procurement.
The study shows the existence of discounts and rebates granted for specific medicines for hospital use. The results suggest product-specific patterns. Hospitals appear to have little leeway to negotiate price reductions for medicines to which no therapeutic alternatives are available. High price reductions, including cost-free provision of medicines, tend to be granted for medicines whose treatment is likely to continue in primary care after discharge of the patient.